HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mia is "sweet" on Splenda

This article was originally published in The Tan Sheet

Executive Summary

Sugar substitute now available in bulk and packet form from McNeil Specialty Products is being promoted by U.S. women's soccer star Mia Hamm. A packet of Splenda, equivalent to two teaspoons of sugar, can save 32 calories compared to sugar, the Calorie Control Council announces Oct. 6. Splenda, a sugar-derived sweetener also known as sucralose, was approved for general use in August 1999 and has been available internationally for several years (1"The Tan Sheet" Aug. 16, 1999, In Brief)

You may also be interested in...



McNeil's Splenda

Sucralose sweetener approved for general use, the company announces Aug. 13. The sucrose-based low calorie sweetener now can be used in all foods and beverages, as well as nutritional supplements, medical foods and vitamin/mineral supplements, the company points out. Splenda, originally approved April 1, 1998 for use in 15 food and beverage categories, is "made from sugar, tastes like sugar and can be used almost anywhere sugar is used"

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel